The mechanism
How Does Semaglutide Work? The Research
From a copied gut hormone to the brain's appetite circuits — the pathway, with the human and animal evidence kept apart.
The gist
How does semaglutide work, in one breath? It copies a hormone your gut releases after a meal, called GLP-1, and makes that signal last about a week instead of two minutes. That signal does several useful things at once: it tells the pancreas to release insulin, but only when blood sugar is high; it quiets a second hormone (glucagon) that would otherwise raise blood sugar; it slows how fast the stomach empties, so you feel full longer; and it reaches appetite centers in the brain to turn down hunger. The weight effect is mostly the brain part — people eat less. The blood-sugar effect is mostly the pancreas part. Below, the pathway is laid out step by step, with one honest flag throughout: the big outcome numbers come from human trials, but much of the fine mechanism was mapped in mice and rats, and this page says which is which.
A copied hormone, engineered to endure
Semaglutide is a long-acting agonist of the GLP-1 receptor — meaning it binds and switches on the same receptor the natural hormone GLP-1 uses. Native GLP-1 is destroyed within about two minutes by an enzyme called DPP-4. Semaglutide dodges that fate two ways: a swapped amino acid at position 8 blocks DPP-4 from cutting it, and a fatty-acid tail lets it cling reversibly to albumin, the blood's most abundant protein, which shields it from the kidneys and stretches its half-life to roughly a week [17]. So the first half of the answer to how semaglutide works is simply persistence: the same signal, kept switched on far longer.
At the pancreas and the stomach
Once the receptor is active, the metabolic effects follow. In the pancreas, semaglutide potentiates glucose-dependent insulin secretion — it amplifies insulin release, but in a way that scales with blood sugar, which is part of why GLP-1 receptor agonists carry a lower direct hypoglycemia risk than some older diabetes drugs. At the same time it suppresses inappropriate glucagon release, lowering the hormone that would push glucose up. And it slows gastric emptying, so food leaves the stomach more gradually and fullness lasts. A 2024 safety-and-mechanism review summarizes this GLP-1 receptor agonism — insulin up when needed, glucagon down, stomach slowed — as the core of the drug's glucose effect [5].
At the brain: where the weight loss lives
The weight effect is largely central, and this is where the evidence is mostly animal — so the flag goes up. In rodents, semaglutide reached the brain directly, accessing the brainstem, the area postrema (a brainstem region with a leaky blood-brain barrier), the hypothalamic arcuate nucleus and the parabrachial nucleus [4]. In the arcuate nucleus it activates the satiety-signaling POMC/CART neurons and inhibits the hunger-driving NPY/AgRP neurons — turning hunger down and fullness up. Crucially, in those studies it reduced food intake and shifted food preference without lowering energy expenditure [4]. The plain reading: the studies frame the weight loss as eating less, not burning more. Because this mapping is rodent work, it is mechanism rather than human outcome — the human outcome is the -14.9% weight change measured in STEP 1 [1].
Why the pieces add up to a weekly shot
Put together, the mechanism explains the dosing. The albumin-binding, DPP-4-resistant design [17] is why one subcutaneous dose covers a week. The glucose-dependent insulin boost and glucagon suppression [5] are why blood sugar improves. The central appetite action [4] is why intake falls and weight comes down. And the slowed stomach is both a feature — longer fullness — and the source of the gut side effects people report most, since nausea and related complaints ride on that same delayed emptying. That trade-off is detailed, with the reported experiences and the cited cautions, on the effects page. The drug's interaction profile is reassuringly quiet: despite the slowed stomach, semaglutide did not meaningfully change the levels of metformin, warfarin, atorvastatin or digoxin [12].